Hemophagocytic lymphohistiocytosis: Diagnosis, pathophysiology, treatment, and future perspectives

Annals of Medicine

Volumn 38, Issue 1, 2006, Pages 20-31

  Verbsky, James W ^b   Grossman, William J ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b NONE

Author keywords

Granzyme; HLH; Perforin; Suppressor; T regulatory cells

Indexed keywords

CYCLOSPORIN A; DEXAMETHASONE; ETOPOSIDE; GAMMA INTERFERON ANTIBODY; GLUCOCORTICOID; IMMUNOGLOBULIN; INFLIXIMAB; INTERLEUKIN 18 ANTIBODY; INTERLEUKIN 6 ANTIBODY; METHOTREXATE; NEUTRALIZING ANTIBODY; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; STEROID;

CANCER CHEMOTHERAPY; CHEDIAK HIGASHI SYNDROME; CLINICAL FEATURE; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; GENE MUTATION; GENETIC DISORDER; GRISCELLI SYNDROME; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; INCIDENCE; INFECTION CONTROL; JUVENILE RHEUMATOID ARTHRITIS; LYMPHOPROLIFERATIVE DISEASE; NATURAL KILLER CELL; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; STEM CELL TRANSPLANTATION; WISKOTT ALDRICH SYNDROME; X CHROMOSOME LINKED DISORDER;

ANIMALS; DIAGNOSIS, DIFFERENTIAL; DNA; HUMANS; IMMUNITY, CELLULAR; IMMUNOLOGIC FACTORS; KILLER CELLS, NATURAL; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; MEMBRANE GLYCOPROTEINS; MUTATION; PORE FORMING CYTOTOXIC PROTEINS; SIGNAL TRANSDUCTION; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 31744445155     PISSN: 07853890     EISSN: 16512219     Source Type: Journal    
DOI: 10.1080/07853890500465189     Document Type: Review

References (110)

1. Henter JI, Elinder G, Soder O, Ost A. Incidence in Sweden and clinical features of familial hemophagocytic lymphohistiocytosis. Acta Paediatr Scan. 1991;80:428-35.
2. Henter JI, Arico M, Elinder G, Imashuku S, Janka G. Familial hemophagocytic lymphohistiocytosis. Primary hemophagocytic lymphohistiocytosis. Hematol Oncol Clin North Am. 1998;12:417-33.
3. Henter JI, Elinder G, Ost A. Diagnostic guidelines for hemophagocytic lymphohistiocytosis. The FHL Study Group of the Histiocyte Society. Semin Oncol. 1991;18: 29-33.
4. Arico M, Janka G, Fischer A, Henter JI, Blanche S, Elinder G, et al. Hemophagocytic lymphohistiocytosis. Report of 122 children from the International Registry. FHL Study Group of the Histiocyte Society. Leukemia. 1996;10:197-203.
5. Dufourcq-Lagelouse R, Pastural E, Barrat FJ, Feldmann J, Le Deist F, Fischer A, et al. Genetic basis of hemophagocytic lymphohistiocytosis syndrome (Review). Int J Mol Med. 1999;4:127-33.
6. Perez N, Virelizier JL, Arenzana-Seisdedos F, Fischer A, Griscelli C. Impaired natural killer activity in lymphohistiocytosis syndrome. J Pediatr. 1984;104:569-73.
7. Arico M, Nespoli L, Maccario R, Montagna D, Bonetti F, Caselli D, et al. Natural cytotoxicity impairment in familial haemophagocytic lymphohistiocytosis. Arch Dis Child. 1988;63:292-6.
8. Sullivan KE, Delaat CA, Douglas SD, Filipovich AH. Defective natural killer cell function in patients with hemophagocytic lymphohistiocytosis and in first degree relatives. Pediatr Res. 1998;44:465-8.
9. Group HLS. HLH-2004: Treatment Protocol of the Second International HLH Study 2004. 2004. (http://histio.org/ society/protocols/trials-protocols.shtml).
10. Henter JI, Elinder G. Cerebromeningeal haemophagocytic lymphohistiocytosis. [see comment]. Lancet. 1992;339: 104-7.
11. Allen M, De Fusco C, Legrand F, Clementi R, Conter V, Danesino C, et al. Familial hemophagocytic lymphohistiocytosis: how late can the onset be? Haematologica. 2001;86:499-503.
12. Ishii E, Ueda I, Shirakawa R, Horiuchi H, Ohga S, Furuno K, et al. Genetic subtypes of familial hemophagocytic lymphohistiocytosis: correlations with clinical features and cytotoxic T lymphocyte/natural killer cell functions. Blood. 2005;105:3442-8.
13. Clementi R, Emmi L, Maccario R, Liotta F, Moretta L, Danesino C, et al. Adult onset and atypical presentation of hemophagocytic lymphohistiocytosis in siblings carrying PRF1 mutations. Blood. 2002;100:2266-7.
14. Janka G, Imashuku S, Elinder G, Schneider M, Henter JI. Infection- and malignancy-associated hemophagocytic syndromes. Secondary hemophagocytic lymphohistiocytosis. Hematol Oncol Clin North Am. 1998;12: 435-44.
15. Imashuku S, Hibi S, Tabata Y, Sako M, Sekine Y, Hirayama K, et al. Biomarker and morphological characteristics of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis. Med Pediatr Oncol. 1998;31: 131-7.
16. Imashuku S, Tabata Y, Teramura T, Hibi S. Treatment strategies for Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH). Leuk Lymphoma. 2000; 39:37-49.
17. Stepp SE, Dufourcq-Lagelouse R, Le Deist F, Bhawan S, Certain S, Mathew PA, et al. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science. 1999;286:1957-9.
18. Masson D, Tschopp J. Isolation of a lytic, pore-forming protein (perforin) from cytolytic T-lymphocytes. J Biol Chem. 1985;260:9069-72.
19. Catalfamo M, Henkart PA. Perforin and the granule exocytosis cytotoxicity pathway. Curr Opin Immunol. 2003; 15:522-7.
20. Raja SM, Metkar S, Froehlich J. Cytotoxic granule-mediated apoptosis: unraveling the complex mechanism. Curr Opin Immunol. 2003;15:528-32.
21. Lieberman J. The ABCs of granule-mediated cytotoxicity: new weapons in the arsenal. Nature Rev Immunol. 2003;3: 361-70.
22. Young JD, Cohn ZA, Podack ER. The ninth component of complement and the pore-forming protein (perforin 1) from cytotoxic T cells: structural, immunological, and functional similarities. Science. 1986;233:184-90.
23. Russell JH, Ley TJ. Lymphocyte-mediated cytotoxicity. Annu Rev Immunol. 2002;20:323-70.
24. Grossman WJ, Revell PA, Lu ZH, Johnson HJ, Bredemeyer AJ, Ley TJ. The orphan granzymes of humans and mice. Curr Opin Immunol. 2003;15:544-42.
25. Kogawa K, Lee SM, Villanueva J, Marmer D, Sumegi J, Filipovich AH. Perforin expression in cytotoxic lymphocytes from patients with hemophagocytic lymphohistiocytosis and their family members. Blood. 2002;99:61-6.
26. Ueda I, Morimoto A, Inaba T, Yagi T, Hibi S, Sugimoto T, et al. Characteristic perforin gene mutations of haemophagocytic lymphohistiocytosis patients in Japan. Br J Haematol. 2003;121:503-10.
27. Ishii E, Ohga S, Tanimura M, Imashuku S, Sako M, Mizutani S, et al. Clinical and epidemiologic studies of familial hemophagocytic lymphohistiocytosis in Japan. Japan LCH Study Group. Med Pediatr Oncol. 1998;30: 276-83.
28. Molleran Lee S, Villanueva J, Sumegi J, Zhang K, Kogawa K, Davis J, et al. Characterisation of diverse PRF1 mutations leading to decreased natural killer cell activity in North American families with haemophagocytic lymphohistiocytosis. J Med Genet. 2004;41:137-44.
29. Feldman J, Callebaut I, Raposo G, Certain S, Bacq D, Dumont C, et al. Munc13-4 is essential for cytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL3). Cell. 2003; 115:461-73.
30. Neeft M, Wieffer M, de Jong AS, Negroiu G, Metz CH, van Loon A, et al. Munc13-4 is an effector of rab27a and controls secretion of lysosomes in hematopoietic cells. Mol Biol Cell. 2005;16:731-41.
31. Rothman JE. Lasker Basic Medical Research Award. The machinery and principles of vesicle transport in the cell. Nat Med. 2002;8:1059-62.
32. Purtilo DT, Cassel CK, Yang JP, Harper R. X-linked recessive progressive combined variable immunodeficiency (Duncan's disease). Lancet. 1975;1:935-40.
33. Hamilton JK, Paquin LA, Sullivan JL, Maurer HS, Cruzi FG, Provisor AJ, et al. X-linked lymphoproliferative syndrome registry report. J Pediatr. 1980;96:669-73.
34. Arico M, Imashuku S, Clementi R, Hibi S, Teramura T, Danesino C, et al. Hemophagocytic lymphohistiocytosis due to germline mutations in SH2D1A, the X-linked lymphoproliferative disease gene. Blood. 2001;97:1131-3.
35. Latour S, Veillette A. Molecular and immunological basis of X-linked lymphoproliferative disease. Immunol Rev. 2003;192:212-24.
36. Latour S, Veillette A. The SAP family of adaptors in immune regulation. Semin Immunol. 2004;16:409-19.
37. Veillette A, Latour S. The SLAM family of immune-cell receptors. Curr Opin Immunol. 2003;15(3):277-85.
38. Sharifi R, Sinclair JC, Gilmour KC, Arkwright PD, Kinnon C, Thrasher AJ, et al. SAP mediates specific cytotoxic T-cell functions in X-linked lymphoproliferative disease. Blood. 2004;103:3821-7.
39. Gaspar HB, Sharifi R, Gilmour KC, Thrasher AJ. X-linked lymphoproliferative disease: clinical, diagnostic and molecular perspective. Br J Haematol. 2002;119:585-95.
40. Klein C, Philippe N, Le Deist F, Fraitag S, Prost C, Durandy A, et al. Partial albinism with immunodeficiency (Griscelli syndrome). J Pediatr. 1994;125:886-95.
41. Pastural E, Ersoy F, Yalman N, Wulffraat N, Grillo E, Ozkinay F, et al. Two genes are responsible for Griscelli syndrome at the same 15q21 locus. Genomics. 2000;63: 299-306.
42. Trambas CM, Griffiths GM. Delivering the kiss of death. Nat Immunol. 2003;4:399-403.
43. Stinchcombe J, Bossi G, Griffiths GM. Linking albinism and immunity: The secrets of secretory lysosomes. Science. 2004;305:55-59.
44. Blott EJ, Griffiths GM. Secretory lysosomes. Nat Rev Mol Cell Biol. 2002;3:122-31.
45. Pastural E, Barrat FJ, Dufourcq-Lagelouse R, Certain S, Sanal O, Jabado N, et al. Griscelli disease maps to chromosome 15q21 and is associated with mutations in the myosin-Va gene. [erratum appears in Nat Genet 1999 Nov;23(3):373]. Nat Genet. 1997;16: 289-92.
46. Menasche G, Pastural E, Feldmann J, Certain S, Ersoy F, Dupuis S, et al. Mutations in RAB27A cause Griscelli syndrome associated with haemophagocytic syndrome. Nat Genet. 2000;25:173-6.
47. Kumar M, Sackey K, Schmalstieg F, Trizna Z, Elghetany MT, Alter BP. Griscelli syndrome: rare neonatal syndrome of recurrent hemophagocytosis. J Pediatr Hematol Oncol. 2001;23:464-8.
48. Stinchcombe JC, Barral DC, Mules EH, Booth S, Hume AN, Machesky LM, et al. Rab27a is required for regulated secretion in cytotoxic T lymphocytes. J Cell Biol. 2001;152:825-34.
49. Stinchcombe JC, Page LJ, Griffiths GM. Secretory lysosome biogenesis in cytotoxic T lymphocytes from normal and Chediak Higashi syndrome patients. Traffic. 2000;1: 435-44.
50. Haddad EK, Wu X, Hammer JA 3rd, Henkart PA. Defective granule exocytosis in Rab27a-deficient lymphocytes from Ashen mice. [see comment]. J Cell Biol. 2001;152:835-42.
51. Blume RS, Wolff SM. The Chediak-Higashi syndrome: studies in four patients and a review of the literature. Medicine. 1972;51:247-80.
52. Introne W, Boissy RE, Gahl WA. Clinical, molecular, and cell biological aspects of Chediak-Higashi syndrome. Mol Genet Metab. 1999;68:283-303.
53. Rubin CM, Burke BA, McKenna RW, McClain KL, White JG, Nesbit ME Jr, et al. The accelerated phase of Chediak-Higashi syndrome. An expression of the virus-associated hemophagocytic syndrome? Cancer. 1985;56: 524-30.
54. Haddad E, Le Deist F, Blanche S, Benkerrou M, Rohrlich P, Vilmer E, et al. Treatment of Chediak-Higashi syndrome by allogenic bone marrow transplantation: report of 10 cases. Blood. 1995;85:3328-33.
55. Baetz K, Isaaz S, Griffiths GM. Loss of cytotoxic T lymphocyte function in Chediak-Higashi syndrome arises from a secretory defect that prevents lytic granule exocytosis. J Immunol. 1995;154:6122-31.
56. Barbosa MD, Nguyen QA, Tchernev VT, Ashley JA, Detter JC, Blaydes SM, et al. Identification of the homologous beige and Chediak-Higashi syndrome genes. [erratum appears in Nature 1997;385:97]. Nature. 1996;382: 262-5.
57. Perou CM, Moore KJ, Nagle DL, Misumi DJ, Woolf EA, McGrail SH, et al. Identification of the murine beige gene by YAC complementation and positional cloning. Nat Genet. 1996;13:303-8.
58. Roder JC, Haliotis T, Laing L, Kozbor D, Rubin P, Pross H, et al. Further studies of natural killer cell function in Chediak-Higashi patients. Immunology. 1982;46: 555-60.
59. Roder JC. Characterization of a murine model (beige) for a natural killer cell immunodeficiency in the Chediak-Higashi syndrome of man. Prog Clin Biol Res. 1982;94: 315-25.
60. Haliotis T, Roder J, Klein M, Ortaldo J, Fauci AS, Herberman RB. Chediak-Higashi gene in humans I. Impairment of natural-killer function. J Exp Med. 1980;151: 1039-48.
61. Ward DM, Shiflett SL, Kaplan J. Chediak-Higashi syndrome: a clinical and molecular view of a rare lysosomal storage disorder. Curr Mol Med. 2002;2:469-77.
62. Sullivan KE, Mullen CA, Blaese RM, Winkelstein JA. A multiinstitutional survey of the Wiskott-Aldrich syndrome. J Pediatr. 1994;125:876-85.
63. Imai K, Morio T, Zhu Y, Jin Y, Itoh S, Kajiwara M, et al. Clinical course of patients with WASP gene mutations. Blood. 2004;103:456-64.
64. Burns S, Cory GO, Vainchenker W, Thrasher AJ. Mechanisms of WASp-mediated hematologic and immunologic disease. Blood. 2004;104:3454-62.
65. Notarangelo LD, Ochs HD. Wiskott-Aldrich Syndrome: a model for defective actin reorganization, cell trafficking and synapse formation. Curr Opin Immunol. 2003;15:585-91.
66. Pasic S, Micic D, Kuzmanovic M. Epstein-Barr virus-associated haemophagocytic lymphohistiocytosis in Wiskott-Aldrich syndrome. Acta Paediatr. 2003;92:859-61.
67. Schmid I, Reiter K, Schuster F, Wintergerst U, Meilbeck R, Nicolai T, et al. Allogeneic bone marrow transplantation for active Epstein-Barr virus-related lymphoproliferative disease and hemophagocytic lymphohistiocytosis in an infant with severe combined immunodeficiency syndrome. Bone Marrow Transplant. 2002;29:519-21.
68. Grunebaum E, Zhang J, Dadi H, Roifman CM. Haemophagocytic lymphohistiocytosis in X-linked severe combined immunodeficiency. Br J Haematol. 2000;108: 834-7.
69. Aleman K, Noordzij JG, de Groot R, van Dongen JJ, Hartwig NG. Reviewing Omenn syndrome. Eur J Pediatr. 2001;160:718-25.
70. Arico M, Bettinelli A, Maccario R, Clementi R, Bossi G, Danesino C. Hemophagocytic lymphohistiocytosis in a patient with deletion of 22q11.2. Am J Med Genet. 1999;87: 329-30.
71. Touraine RL, Pondarre C, Till M, Bertrand Y. Hemophagocytic lymphohistiocytosis and del22q11 [abstract]. Genetic Counseling. 1999;10:114-5.
72. Osugi Y, Hara J, Tagawa S, Takai K, Hosoi G, Matsuda Y, et al. Cytokine production regulating Th1 and Th2 cytokines in hemophagocytic lymphohistiocytosis. Blood. 1997;89:4100-3.
73. Schneider EM, Lorenz I, Muller-Rosenberger M, Steinbach G, Kron M, Janka-Schaub GE. Hemophagocytic lymphohistiocytosis is associated with deficiencies of cellular cytolysis but normal expression of transcripts relevant to killer-cell-induced apoptosis. Blood. 2002;100: 2891-8.
74. Takada H, Nomura A, Ohga S, Hara T. Interleukin-18 in hemophagocytic lymphohistiocytosis. Leuk Lymphoma. 2001;42:21-8.
75. Takada H, Takahata Y, Nomura A, Ohga S, Mizuno Y, Hara T. Increased serum levels of interferon-gamma-inducible protein 10 and monokine induced by gamma interferon in patients with haemophagocytic lymphohistiocytosis. Clin Exp Immunol. 2003;133:448-53.
76. Takada H, Ohga S, Mizuno Y, Nomura A, Hara T. Increased IL-16 levels in hemophagocytic lymphohistiocytosis. J Pediatr Hematol Oncol. 2004;26:567-73.
77. Billiau AD, Roskams T, Damme-Lombaerts R, Matthys P, Wouters C. Macrophage activation syndrome: characteristic findings on liver biopsy illustrating the key role of activated, IFN-gamma-producing lymphocytes and IL-6- and TNF-alpha-producing macrophages. Blood. 2005;105:1648-51.
78. Grossman WJ, Radhi M, Schauer D, Gerday E, Grose C, Goldman FD. Development of hemophagocytic lymphohistiocytosis in triplets infected with HHV-8. Blood. 2005;106:1203-06.
79. Grom AA, Villanueva J, Lee S, Goldmuntz EA, Passo MH, Filipovich A. Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome. J Pediatr. 2003;142:292-6.
80. Wulffraat NM, Rijkers GT, Elst E, Brooimans R, Kuis W. Reduced perforin expression in systemic juvenile idiopathic arthritis is restored by autologous stem-cell transplantation. Rheumatology (Oxford). 2003;42:375-9.
81. Kagi D, Ledermann B, Burki K, Seiler P, Odermatt B, Olsen KJ, et al. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature. 1994;369:31-7.
82. Walsh CM, Matloubian M, Liu CC, Ueda R, Kurahara CG, Christensen JL, et al. Immune function in mice lacking the perforin gene. Proc Natl Acad Sci U S A. 1994;91:10854-8.
83. Mullbacher A, Hla RT, Museteanu C, Simon MM. Perforin is essential for control of ectromelia virus but not related poxviruses in mice. J Virol. 1999;73:1665-7.
84. Ghiasi H, Cai S, Perng G, Nesburn AB, Wechsler SL. Perforin pathway is essential for protection of mice against lethal ocular HSV-1 challenge but not corneal scarring. Virus Res. 1999;65:97-101.
85. Rossi CP, McAllister A, Tanguy M, Kagi D, Brahic M. Theiler's virus infection of perforin-deficient mice. J Virol. 1998;72:4515-9.
86. Kagi D, Ledermann B, Burki K, Hengartner H, Zinkernagel RM. CD8+ T cell-mediated protection against an intracellular bacterium by perforin-dependent cytotoxicity. Eur J Immunol. 1994;24:3068-72.
87. Denkers EY, Yap G, Scharton-Kersten T, Charest H, Butcher BA, Caspar P, et al. Perforin-mediated cytolysis plays a limited role in host resistance to Toxoplasma gondii. J Immunol. 1997;159:1903-8.
88. Zhou P, Freidag BL, Caldwell CC, Seder RA. Perforin is required for primary immunity to Histoplasma capsulatum. J Immunol. 2001;166:1968-74.
89. Jordan MB, Hildeman D, Kappler J, Marrack P. An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder. Blood. 2004;104:735-43.
90. Matloubian M, Suresh M, Glass A, Galvan M, Chow K, Whitmire JK, et al. A role for perforin in downregulating T-cell responses during chronic viral infection. J Virol. 1999;73:2527-36.
91. Badovinac VP, Hamilton SE, Harty JT. Viral infection results in massive CD8+ T cell expansion and mortality in vaccinated perforin-deficient mice. Immunity. 2003;18: 463-74.
92. Kagi D, Odermatt B, Mak TW. Homeostatic regulation of CD8+ T cells by perforin. Eur J Immunol. 1999;29: 3262-72.
93. Peng SL, Moslehi J, Robert ME, Craft J. Perforin protects against autoimmunity in lupus-prone mice. J Immunol. 1998;160:652-60.
94. Spielman J, Lee RK, Podack ER. Perforin/Fas-ligand double deficiency is associated with macrophage expansion and severe pancreatitis. J Immunol. 1998;161:7063-70.
95. Malipiero U, Frei K, Spanaus KS, Agresti C, Lassmann H, Hahne M, et al. Myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis is chronic/relapsing in perforin knockout mice, but monophasic in Fas- and Fas ligand-deficient lpr and gld mice. Eur J Immunol. 1997;27:3151-60.
96. Liu B, Mori I, Hossain MJ, Dong L, Chen Z, Kimura Y. Local immune responses to influenza virus infection in mice with a targeted disruption of perforin gene. Microb Pathog. 2003;34:161-7.
97. Kemper C, Chan AC, Green JM, Brett KA, Murphy KM, Atkinson JP. Activation of human CD4+ cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype. Nature. 2003;421:388-92.
98. Grossman WJ, Verbsky JW, Barchet W, Colonna M, Atkinson JP, Ley TJ. Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity. 2004;21:589-601.
99. Grossman WJ, Verbsky JW, Tollefson BL, Kemper C, Atkinson JP, Ley TJ. Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells. Blood. 2004;104:2840-8.
100. Grossman WJ, Verbsky JW, Yang L, Berg LJ, Fields LE, Chaplin DD, et al. Dysregulated myelopoiesis in mice lacking Jak3. Blood. 1999;94:932-9.
101. Henter JI, Elinder G, Finkel Y, Soder O. Successful induction with chemotherapy including teniposide in familial erythrophagocytic lymphohistiocytosis. Lancet. 1986;2:1402.
102. Fisher A, Virelizier JL, Arenzana F, Perez A, Nezelof C, Griscelli C. Treatment of four patients with erythrophagocytic lymphohistiocytosis by a combination of epipodophyllotoxin, steroids, intrathecal methotrexate and cranial irradiation. Pediatrics. 1985;76:263-8.
103. Bolme P, Henter JI, Winiarski J, Elinder G, Ljungman P, Lonnerholm G, et al. Allogeneic bone marrow transplantation for hemophagocytic lymphohistiocytosis in Sweden. Bone Marrow Transplant. 1995;15:331-5.
104. Baker KS, DeLaat CA, Steinbuch M, Gross TG, Shapiro RS, Loechelt B, et al. Successful correction of hemophagocytic lymphohistiocytosis with related or unrelated bone marrow transplantation. Blood. 1997;89: 3857-63.
105. Henter JI, Samuelsson-Horne A, Arico M, Egeler RM, Elinder G, Filipovich AH, et al. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood. 2002;100: 2367-73.
106. Ishii E, Ohga S, Aoki T, Yamada S, Sako M, Tasaka H, et al. Prognosis of children with virus-associated hemophagocytic syndrome and malignant histiocytosis: correlation with levels of serum interleukin-1 and tumor necrosis factor. Acta Haematol. 1991;85:93-9.
107. Imashuku S, Hibi S, Fujiwara F, Ikushima S, Todo S. Haemophagocytic lymphohistiocytosis, interferon-gamma-naemia and Epstein-Barr virus involvement. Br J Haematol. 1994;88:656-8.
108. Henter JI, Elinder G, Soder O, Hansson M, Andersson B, Andersson U. Hypercytokinemia in familial hemophagocytic lymphohistiocytosis. Blood. 1991;78:2918-22.
109. Verbsky JW, White AJ. Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J Rheumatol. 2004;31:2071-5.
110. Fisman DN. Hemophagocytic syndromes and infection. Emerg Infect Dis. 2000;6:601-8.